Spero Therapeutics, Inc.
SPRO
$2.30
-$0.02-0.86%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -59.83% | -53.77% | 37.01% | 118.43% | 107.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.83% | -53.77% | 37.01% | 118.43% | 107.40% |
| Cost of Revenue | 69.77% | 95.90% | 166.67% | 122.56% | 94.17% |
| Gross Profit | -308.07% | -302.20% | -64.92% | 105.72% | 145.06% |
| SG&A Expenses | 1.89% | -7.24% | -9.90% | -11.11% | -15.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.14% | 56.46% | 42.30% | 44.64% | 23.28% |
| Operating Income | -370.26% | -370.59% | -152.27% | 257.49% | 285.32% |
| Income Before Tax | -368.31% | -369.90% | 504.69% | 298.86% | 196.83% |
| Income Tax Expenses | -100.00% | -100.00% | -95.61% | -- | -- |
| Earnings from Continuing Operations | -398.09% | -400.65% | 317.66% | 273.10% | 187.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -398.09% | -400.65% | 317.66% | 273.10% | 187.16% |
| EBIT | -370.26% | -370.59% | -152.27% | 257.49% | 285.32% |
| EBITDA | -366.85% | -366.60% | -137.87% | 266.94% | 298.48% |
| EPS Basic | -390.00% | -397.61% | 756.84% | 232.26% | 149.19% |
| Normalized Basic EPS | -313.30% | -317.34% | -44.86% | 287.04% | 235.76% |
| EPS Diluted | -391.83% | -399.55% | 731.58% | 231.32% | 148.92% |
| Normalized Diluted EPS | -314.00% | -318.07% | -46.13% | 286.30% | 235.32% |
| Average Basic Shares Outstanding | 2.92% | 2.53% | 3.91% | 12.39% | 24.52% |
| Average Diluted Shares Outstanding | 2.87% | 2.48% | 3.97% | 12.44% | 24.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |